SCHEMBL1196540

SCHEMBL1196540

COC(=O)C(N)Cc1c[nH]c2cc(F)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.53
HTR2C P28335 2/20 0.53
GPR84 Q9NQS5 1/20 0.51
TACR1 P25103 2/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
NR3C1 P04150 1/20 0.48
PTPRA P18433 1/20 0.48
KDM4E B2RXH2 2/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
TSHR P16473 2/20 0.47
BLM P54132 2/20 0.47
PMP22 Q01453 2/20 0.47
MPO P05164 1/20 0.47
HIF1A Q16665 1/20 0.47
SCN9A Q15858 1/20 0.47
CYP2C19 P33261 1/20 0.46
ADAM17 P78536 1/20 0.46
HTR1A P08908 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165731 1.00 HTR2A (0.53) HTR2AHTR2CGPR84TACR1KMT2A
Hydrochloric Acid SCHEMBL6729099 0.99 HTR2A (0.52) HTR2AHTR2CGPR84TACR1KMT2A
Hydrochloric Acid SCHEMBL6729101 0.99 HTR2A (0.52) HTR2AHTR2CGPR84TACR1KMT2A
SCHEMBL1195736 0.90 HTR2A (0.64) HTR2AHTR2CGPR84TACR1KMT2A
SCHEMBL5165399 0.90 HTR2A (0.64) HTR2AHTR2CGPR84TACR1KMT2A
Hydrochloric Acid SCHEMBL6729297 0.89 HTR2A (0.62) HTR2AHTR2CGPR84TACR1KMT2A
Hydrochloric Acid SCHEMBL6729301 0.89 HTR2A (0.62) HTR2AHTR2CGPR84TACR1KMT2A
SCHEMBL24113523 0.86 TACR1 (0.57) HTR2AHTR2CTACR1KMT2AMEN1
SCHEMBL29180770 0.86 PTPRA (0.52) HTR2AHTR2CTACR1KMT2AMEN1
SCHEMBL30310544 0.86 TACR1 (0.57) HTR2AHTR2CTACR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110027226-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) 4SC AG (DE) 2011-02-03 US disclosed
EP-2033962-A1 Tetracyclic indolopyridines as EG5 inhibitors 4SC AG (DE) 2009-03-11 EP disclosed
EP-1914235-A1 CHIRAL TETRA-HYDRO BETA-CARBOLINE DERIVATIVES AND APPLICATIONS THEREOF AS ANTIPARASITIC COMPOUNDS Universite de Lille 2 Droit et Santé (FR) 2008-04-23 EP disclosed
EP-1914235-A1 CHIRAL TETRA-HYDRO BETA-CARBOLINE DERIVATIVES AND APPLICATIONS THEREOF AS ANTIPARASITIC COMPOUNDS Universite de Lille 2 Droit et Santé (FR) 2008-04-23 EP disclosed
WO-2008044144-A2 CHIRAL TETRA-HYDRO BETA-CARBOLIC DERIVATIVES AND APPLICATIONS THEREOF AS ANTIPARASITIC COMPOUNDS UNIVERSITE DE LILLE 2, UNIVERSITÉ DU DROIT ET DE LA SANTÉ (FR) 2008-04-17 WO disclosed
US-7276518-B2 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2007-10-02 US disclosed
CN-1186344-C Amino acid compounds and their use as NEP, ACE and ECE inhibitors INST NAT RECH MEDICALE INSERM (FR) 2005-01-26 CN disclosed
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity GRUENENTHAL GMBH (DE) 2004-11-18 US disclosed
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2004-08-19 US disclosed
US-6716852-B2 FOR THERAPY OF ARTERIAL HYPERTENSION AND CARDIOVASCULAR DISEASES LES LABORATORIES SERVIER (FR) 2004-04-06 US disclosed
US-20030055086-A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors LES LABORATOIRES SERVIER (FR) 2003-03-20 US disclosed
CN-1400974-A Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors INST NAT RECH MEDICALE INSERM (FR) 2003-03-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds DPYD, DDC, QDPR HTR2A 325/4885HTR2C 247/4885GPR84 3151/4885
US-20110027226-A1 INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) KIF5A, KIF5C, KIF5B HTR2A 3694/4885HTR2C 3971/4885GPR84 3688/4885
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity ARG1, CD2, PDCD1 HTR2A 1192/4885HTR2C 1917/4885GPR84 893/4885
US-20030055086-A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors MME, ACE, ECE1 HTR2A 464/4885HTR2C 201/4885GPR84 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.